How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.
Pharma & Biotech